ReviewMolecular diagnosis & therapy2008
The role of molecular markers in predicting response to therapy in patients with colorectal cancer.
Review in Molecular diagnosis & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Prognostic Significance of Serum Lactic Acid, Lactate Dehydrogenase, and Albumin Levels in Patients with Metastatic Colorectal Cancer.BioMed research international · 2018Trial
- A complex microsatellite at chromosome 7q33 as a new prognostic marker of colorectal cancer.Oncotarget · 2017Article
- Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.Molecular diagnosis & therapy · 2012Review
- Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?Clinical colorectal cancer · 2011Review
- Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2011Review
- Mass spectrometry protein expression profiles in colorectal cancer tissue associated with clinico-pathological features of disease.BMC cancer · 2010Article
- Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study.World journal of surgical oncology · 2010Article
- A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.The oncologist · 2010Review
- Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment.International journal of colorectal disease · 2009Review
- Evolution of nonsurgical therapy for colorectal cancer.Nature clinical practice. Gastroenterology & hepatology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in systemic therapy for colorectal cancer have dramatically improved prognosis. While disease stage has traditionally been the main determinant of disease course, several molecular characteristics of tumor specimens have recently been shown to have prognostic significance. Although to date no molecular characteristics have emerged as consistent predictors of response to therapy, retrospective studies have investigated the role of a variety of biomarkers, including microsatellite instability, loss of heterozygosity of 18q, type II transforming growth factor beta receptor, thymidylate synthase, epidermal growth factor receptor, and Kirsten-ras (KRAS). This paper reviews the current literature, ongoing prospective studies evaluating the role of these markers, and novel techniques such as gene profiling, which may help to uncover the more complex molecular interactions that will predict response to chemotherapy in patients with colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.